Straight talk.
Hard topics.
Smart people.
Post-Administration Imaging of Radiotherapeutics.
The Bexxar Experience: The pros and cons of on-label dosimetry.
The Digital Twin: Let’s make it a reality.
Do You Have a Defensible Position?
Multi-Timepoint Imaging: They do come back.
RPT Dosimetry Reimbursement: A clinical reality.
Managing RPT Workflows: Lessons learned.
Finding Opportunity in RPT Uncertainty.
Another Pandora’s Box: Quality assurance & standardization.
Into the Great Unknown: Maximum tolerated activity.
Accelerate Your Science!
Why do Drug Developers do so Many Trials "Down Under"?
Relevance of Traceability for Dosimetry.
Do You Know Where Your Daughter Is?
Let's Talk
Your host, Dr. Sue Wallace, CEO of Voximetry kicks off the Let’s Talk thought leader series by sharing her vision for listening, sharing, and community engagement to advance clinical RPT dosimetry and achieve a new standard of personalized cancer care.
Dr. Richard Wahl shares current practices and the evolving topic of post-administration imaging of radiotherapeutics to establish a baseline for disease state.
In Part 2 of this series, Dr. Wahl reflects upon the advent of theranostics and the advancements, obstacles and outlook for RPT dosimetry to advance personalized care for late-stage cancer patients.
test
Research scientist, Julia Brosch-Lenz explains the benefits of developing a theranostics blueprint to model treatment options and outcomes and the need for global clinical data sharing to make the promise of the digital twin a reality.
test